Clinical Trials

Phase 1 Active not recruiting

712 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

NCT06077500 2026-04-14

DAREONᵀᴹ-8

46 enrolled

Small Cell Lung Carcinoma

NCT06161532 2026-04-14

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Phase 2 Recruiting

60 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT07155174 2026-04-14

SEZanne

Phase 2 Recruiting

180 enrolled

Phase 2/3 Active not recruiting

Small Cell Lung Carcinoma

NCT07291076 2026-04-14

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Phase 1/2 Recruiting

129 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT02839707 2026-04-13

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

444 enrolled 17 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02883062 2026-04-13

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

67 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02997228 2026-04-13

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

120 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03141684 2026-04-13

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

63 enrolled 2 FDA

Sarcoma

Sarcoma, Alveolar Soft Part

NCT03148418 2026-04-13

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

382 enrolled

Tumor-Agnostic

Neoplasms

NCT03237780 2026-04-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Phase 1 Active not recruiting

72 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03321643 2026-04-13

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

24 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03540420 2026-04-13

ACHILES

212 enrolled

Small Cell Lung Carcinoma

NCT03694262 2026-04-13

EndoBARR

Phase 2 Completed

30 enrolled 7 charts

Gynecologic

Endometrial Neoplasms

NCT03775265 2026-04-13

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

475 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03811002 2026-04-13

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

544 enrolled 29 charts

Lung Neoplasms

NCT04214262 2026-04-13

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

480 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04310020 2026-04-13

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

47 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04334941 2026-04-13

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

103 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT04458922 2026-04-13

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma